RxDoctor Payments Data

Justin Charton, MD

Ophthalmology · Conway, ARNPI 1881897817

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.4% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $476, more than ten times the $15 reported in 2019.

$1,057in general payments, 2019–2025

Across 46 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$229
  • Alcon$213
  • Bausch & Lomb Americas Inc.$161
  • Biotissue Holdings Inc.$139
  • Rxsight Inc$98
  • Novartis$98
  • plus $120 from 3 others

What the payments were for

  • Food & beverage$97892%
  • Education$808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,057 in reported general payments places this provider in the 60th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$548,089
Medicare patients
1,765
Services billed
4,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine145$167,161
XiidraLifitegrast50$64,527
ProlensaBromfenac Sodium104$36,205
Cyclosporine28$21,867
Prednisolone Acetate402$18,001
Latanoprost768$8,843
IlevroNepafenac18$6,703
LumiganBimatoprost13$6,105
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$5,238
Travoprost29$4,822
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat187$3,511
Timolol Maleate404$3,396
Ketorolac Tromethamine131$2,280
SimbrinzaBrinzolamide/Brimonidine Tart11$2,267
Bromfenac Sodium12$2,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$229$173,266158 claims
Bausch & Lomb Americas Inc.Xiidra$161$64,52750 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$37$36,205104 claims
NovartisIlevro$98$6,70318 claims
AlconSimbrinza$213$2,26711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →